Table 3.
Admission laboratory values, pattern, and degree of liver injury
| n | CAM-induced liver injury |
n | PM-induced liver injury | P value | |
|---|---|---|---|---|---|
| Laboratories, median [IQR] | 41a | 209a | |||
| ALT (IU/l) | 769 [293–1,769] | 659 [269–1,592] | 0.50 | ||
| AST (IU/l) | 579 [335–1,609] | 649 [269–1,349] | 0.80 | ||
| Alkaline phosphate (IU/l) | 125 [103–182] | 171 [123–232] | <0.01 | ||
| INR | 2.7 [1.9–3.8] | 2.4 [1.9–3.5] | 0.28 | ||
| Platelet count (×1,000/mm3) | 150 [115–223] | 139.5 [91–209] | 0.28 | ||
| Bilirubin (mg/dl) | 18.2 [9.9–28.1] | 19.0 [12.1–26.6] | 0.80 | ||
| MELD | 31.7 [26.4–37.1] | 31.5 [26.6–36.9] | 0.99 | ||
| Pattern of injury/R score (%) | 40 | 203 | |||
| Hepatocellular | 32 (80) | 148 (73) | |||
| Mixed | 7 (18) | 33 (16) | 0.26 | ||
| Cholestatic | 1 (2) | 22(11) | |||
| Degree of injury—ALI/ALF (%)b | 41 | 210 | |||
| ALI | 5 (12) | 19 (9) | |||
| ALI progressed to ALF | 4 (10) | 5 (2) | 0.16 | ||
| ALF | 32 (78) | 186 (89) |
ALF, acute liver failure; ALFSG, Acute Liver Failure Study Group; ALI, acute liver injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAM, complementary and alternative medicine; INR, international normalized ratio; IQR, interquartile range; MELD, Model of End-Stage Liver Disease; PM, prescription medication.
a
Incomplete data on all patients. Sample size ranges for subset of data: CAM n=39–41 and PM n=203–209.
b
ALFSG began collecting data on patients with ALI in 2008.